Olaf
Klingbeil

VIB–KU Leuven Center for Cancer Biology, BE

Olaf Klingbeil is a group leader at the VIB–KU Leuven Center for Cancer Biology (CCB) and an assistant professor in the Department of Cellular and Molecular Medicine at KU Leuven, where he heads the Laboratory for Functional Genomics and Gene Regulation. He earned his doctorate (Dr. rer. nat.) at Humboldt University Berlin in collaboration with Bayer Pharma, then spent his postdoctoral years (2017–2024) at Cold Spring Harbor Laboratory before starting his own group in 2025.

His lab studies how cancer cells adapt to therapy and become resistant. Rather than treating resistance as a fixed genetic endpoint, his group views it as a dynamic, time-dependent process — asking not only which genes and pathways matter, but when they act, in what order, and whether their effects can be reversed. This work is anchored in pancreatic ductal adenocarcinoma (PDAC), a cancer notorious for its plasticity and treatment resistance, though the underlying questions apply broadly across cancer types.

To get at these questions, the lab builds and applies CRISPR-based functional genomics — the focus of this course. This includes pooled single-gene and combinatorial screens, paralog-targeting strategies that expose redundancy simpler screens miss, and inducible systems that add temporal control, read out with single-cell and chromatin profiling. As one example of what the approach reveals, he used paralog-focused CRISPR screening to identify the MARK2 and MARK3 kinases as catalytic co-dependencies of YAP/TAZ signaling — a redundancy-driven resistance mechanism that candidate-by-candidate methods would have missed.

Today his group is building a dedicated CRISPR functional genomics platform at VIB–KU Leuven Center for Cancer Biology, supported by an FWO Odysseus grant, to map how signaling and transcriptional networks reorganize under therapeutic pressure.